ArticleJournal of translational medicine2026
Spatial and single-cell transcriptomic profiling reveals interplay between SRGN-associated epithelial programs and C1QC+ macrophages in early LUAD progression.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundDeciphering the molecular and cellular mechanisms underlying the progression of early-stage lung adenocarcinoma (LUAD) is critical for advancing early detection and therapeutic strategies. This study aims to map the evolutionary trajectory from precursor lesions to invasive adenocarcinoma.
methodsWe integrated single-cell RNA sequencing (scRNA-seq) and spatial transcriptomic analyses to evaluate LUAD progression across four histologic stages:atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), and invasive adenocarcinoma (IAC). Findings were further validated using a stage-specific A/J mouse model to confirm functional cellular interactions.
resultsWe identified a tumor-intrinsic program characterized by elevated SRGN expression that is associated with Epithelial-Mesenchymal Transition (EMT) and cell proliferation, intensifying as the disease progresses. In parallel, a stage-dependent accumulation of C1QC+ macrophages was observed. Spatial colocalization analysis revealed that SRGN+ malignant cells and C1QC+ macrophages are closely positioned within the tumor microenvironment. We detected progressively enhanced interactions between SRGN+ malignant cells and both exhausted T cells and C1QC+ macrophages, mediated by specific receptor-ligand pairs, including MIF-LIFR, ADAM17-ERBB4, OSM-EGFR, and OSM-TNFRSF14. The A/J mouse models confirmed the co-emergence and functional cooperation of these populations.
conclusionsOur findings highlight a coordinated epithelial-macrophage module that drives LUAD progression. The identification of SRGN and its associated spatial interactions offers potential molecular targets for early therapeutic intervention and diagnostic modeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.